Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:

Scottish ProStrakan, JapanBridge Ink Sancuso Licensing Deal For Japan, China, And Southeast Asia

This article was originally published in PharmAsia News

Executive Summary

SHANGHAI - Scotland-based ProStrakan Group has granted JapanBridge K.K. an exclusive license to develop and commercialize antiemetic Sancuso (granisetron) in Japan, mainland China, Taiwan, Singapore and Malaysia, the companies announced May 23

You may also be interested in...



Kyowa Hakko Kirin And Solasia Begin Effort To Bring Cancer Support Therapies To Asia

Kyowa Hakko Kirin and Solasia Pharma are rolling out the first result of their partnership to bring Western oncology products to Asia, announcing a commercialization agreement that grants Kyowa Hakkko Kirin rights to sell ProStrakan's extended release transdermal Sancuso in some Asian countries

PharmAsia News Business Bulletin

A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).

Table

View full table

Tags:
Latest Headlines

How Ochre Bio Bagged Boehringer For Its RNA-Based Regenerative MASH Therapies

IGI Bets On Trispecific Antibody To Make Inroads Into Big Pharma Myeloma Turf

Chinese Firms Up Their Game In Novel Flu Antiviral Development

Quotable: Words Of Wisdom From Our Recent APAC Coverage

See All
UsernamePublicRestriction

Register

SC068661

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By